C-demethylation and 1, 2-amino shift in (E)-2-(1-(3-aminophenyl) ethylidene)hydrazinecarboxamide to (E)-2-(2-aminobenzylidene) hydrazinecarboxamide and their applications

M. Sennappan¹,², Sinosh Skariyachan³, Praveen B. Managutti⁴ & Shubha Shridhar Gunaga⁴

A Novel (E)-2-(1-(3-aminophenyl)ethylidene)hydrazinecarboxamide 1 was synthesized by traditional method and converted to (E)-2-(2-aminobenzylidene)hydrazinecarboxamide 2 by single step in DMSO at room temperature. Synthesized compound 1 was analysed by spectroscopy (NMR and LC–MS) techniques and molecule 2 was characterized using single crystal X-ray diffraction and spectroscopy (NMR and GC–MS) techniques. These analytical technique results revealed that, C-demethylation and 1, 2 amino shift in phenyl ring of compound 1 gives molecule 2. DNA binding studies of compounds 1 and 2 was carried out by electronic absorption spectroscopy. This result revealed that, compounds 1 and 2 showed hyperchromism with bathochromic shift. Anticancer activity of compounds 1 and 2 is carried out by molecular docking with five receptors. Computer aided virtual screening demonstrated that the synthesized molecules possess ideal drug likeliness, pharmacokinetics features, toxicity profile for structure based drug discovery. The molecular docking studies revealed that the synthesized molecules are significant binding with the five selected cancer receptors with minimum binding energy (kcal/mol), number of hydrogen bonds, weak interaction, docking score and cluster RMS. The docking studies also suggested that the molecules showed interactions with DNA and the theoretical values of the binding are comparable with that of the experimental values. Hirshfeld surface analysis was used to analyze and quantify the intermolecular interactions in the crystal structure of compound 2.

Semicarbazones are organic compounds possessing azomethine and urea functions, which are pharmacophores¹⁻⁴. Semicarbazones have been extensively investigated owing to their potential applications in biological and pharmacological fields⁵⁻⁷. These are important classes of compounds which can coordinate with many metal ions because of the presence of donor atoms such as nitrogen and oxygen in their core structure⁸⁻¹⁰. In biological systems, C-demethylation occur in histones and DNA, catalysed by enzymes/chemical agents¹¹⁻¹². This is widely used in various therapeutic areas includes cancer, infectious diseases, inflammation, immunology, dermatology, epigenetics, psychiatric disease etc.¹³⁻¹⁶. O-demethylation is occurred in methyl ethers and methyl esters and N-demethylation in tertiary amines using harsh chemical reagents/conditions¹⁷⁻²⁴. These chemical demethylation is used to make several valuable molecules like paroxetine, atamine, morphine etc.²²⁻²⁴. In biological systems, 1,2 amino shift is observed in aliphatic/aliphatic position of aromatic compounds which is catalyzed by aminomutases, B6 and B12²⁵. The recent surveys and studies revealed that the synergistic effect of aromatic compounds significantly reduces the risk of cancer mortality. Anticancer drugs approved by FDA in 2018 are Vitrakvi, Lorbrerna, Talzenna, Vizimpro, Akyzuo, Erleada, Lutathera etc.²⁶. All are aromatic molecules possessing substitutents such as O, N, S, Cl, F etc. Substitutents are having lone pair of electrons which makes the molecules biologically and pharmacologically potent²⁷. In contrast, platinum based chemotherapeutic agents are most...
widely used drugs in treatment of various cancers. Their remarkable success has been marred somehow because of several side effects such as nephrotoxicity, adverse effects on the peripheral nervous system as well as liver damage, severe emesis and drug resistant tumors etc. Limitations of platinum based drugs arouse to design novel organic molecules as anticancer drugs. DNA binding mechanism of molecules has been studied in order to develop anticancer drugs. Organic molecules interact with DNA helix structure through an intercalation/non-intercalation process intervene with the cell cycle such as translation, transcription and replication causing cell death. In the light of above, detailed analyses of structure of novel synthesized semicarbazones are completed by different analytical techniques. The interaction mechanism of molecules with nucleic acid by electronic absorption spectroscopy were carried out. Anticancer activity of compounds 1 and 2 is carried out by molecular docking with five receptors and ideal drug likeness, pharmacokinetics features, toxicity profile for structure based drug discovery of compounds 1 and 2 were evaluated using computer aided virtual screening. An estimation of close intermolecular interactions in the compound 2 is also reported using Hirshfeld surface analysis.

**Results and discussion**

The compound was kept for crystallization in polar solvent DMSO; the polar solvent attacked the carbonyl group of compound 1 gives carbanion as intermediate. The carbanion lost methyl group along with bonding electrons as methyl anion and also solvent regaining its original state given carbocation. The positive ion moves towards the phenyl ring and also shifting of proton from phenyl ring to azomethine carbon takes place. So that it produces positive charge on phenyl ring carbon, it is ortho position to amine group. However, 1, 2 shift of amino group in a phenyl ring and addition of hydride ion from methyl anion gave stable compound 2. The intermediates of this conversion carbanion, carbocations and nitronium ion are stabilized by resonance, since molecule 1 has double bonds and heteroatoms in conjugation throughout the molecule. Conversion mechanism is given in Scheme 1.

**Single crystal X-ray diffraction studies.** The structure of molecule 2 with labeling of atoms, hydrogen bonds and packing diagram is given in Figs. 1, 2 and 3. Selected bond angles, bond lengths and hydrogen bonding data are listed in Tables 1 and 2. The C2-N3 bond length is 1.281(3) Å indicates that it is a characteristic of azomethine group. Phenyl group in a molecule is delocalized bonding structure, confirms C–C bond lengths of ring in the ranging from 1.371(5) to 1.401(4) Å. The bond length of C1–O1 is 1.250(3) Å; it is a characteristic of amide carbonyl group of semicarbazone. The bond lengths of C4–N4 1.355(3) Å, N4–H4B 0.860(0) Å and...
Figure 2. Unit cell packing diagram of molecule, 2.

Figure 3. Structure of molecule 2 with hydrogen bonds.

| Atom | Atom | Length/Å | Atom | Atom | Angle/° |
|------|------|----------|------|------|---------|
| O1   | C1   | 1.250(3) | C2   | N3   | 116.3(2)        |
| N3   | N2   | 1.373(3) | C1   | N2   | 121.3(2)        |
| N3   | C2   | 1.281(3) | C4   | C3   | 122.6(2)        |
| N1   | C1   | 1.329(3) | C4   | C3   | 118.4(2)        |
| N2   | C1   | 1.359(3) | C8   | C3   | 119.0(2)        |
| N4   | C14  | 1.355(3) | C1   | N1   | 123.1(2)        |
| C3   | C2   | 1.454(3) | O1   | C1   | 118.2(2)        |
| C3   | C4   | 1.391(4) | N1   | C1   | 118.7(2)        |
| C3   | C6   | 1.401(4) | N3   | C2   | 122.5(2)        |
| C4   | C5   | 1.399(4) | N4   | C4   | 121.1(2)        |
| C8   | C7   | 1.379(4) | N4   | C4   | 119.0(3)        |
| C7   | C6   | 1.381(5) | C5   | C4   | 119.9(3)        |
| C6   | C5   | 1.371(5) | C7   | C8   | 121.1(3)        |
| N4   | H4A  | 0.8600(0) | C8   | C7   | 119.6(3)        |
| N4   | H4B  | 0.8600(1) | C5   | C6   | 120.1(3)        |

Table 1. Bond lengths and bond angles of compound 2.
N4-H4 0.860(1) Å, these bonds reveals that amino group attached to phenyl ring33. The conformation of molecule is stabilized by hydrogen bonds.

DNA binding studies. The electronic spectral data of compounds 1 and 2 were recorded in the absence and presence of rising amounts of CT-DNA (25 µL—350 µL). Arrow shows the increase absorbance with increase the DNA concentration. Inset: plot of [DNA]/ (εa-εf) Vs [DNA].

Computer aided virtual screening studies. The predicted drug likeliness features of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazine carboxamide and (E)-2-(2-aminobenzylidene) hydrazinecarboxamide are shown Table 3. From the table, it is clear that both the molecules are found to be suitable for various drugs
like filters. The molecular refractivity, TPSA and Log Po/w and bioavailability score were in reliable cut off required for the computational screening. The filtering of the drug like features by various Cheminformatics filters showed that molecules are suitable for Ghose filter, Veber filter, Egan filter, Lipinski rule and CMC like rule. However, (E)-2-(2-aminobenzylidene) hydrazinecarboxamide showed violation of Lead like rule and Muegge filter. The drug like prediction by world drug index (WDI) like rule indicated that molecules are in 90% cutoff; it is ideal features for the lead molecules. The pharmacokinetic features of the two selected lead molecules are shown in Table 4. From the table, it is clear that, the two molecules showed almost similar pharmacokinetics features. Blood brain barrier permeability, Buffer solubility, human epithelial colorectal adenocarcinoma cell permeability, CYP inhibition, human intestinal absorption, plasma protein binding, pure water solubility and skin permeability models showed various values, signifies that most the pharmacokinetic features are in the acceptable range for ideal drug. The toxicity features of the selected lead molecules are shown in Table 5. The study indicated that, both molecules showed positive for carcinogenicity in mouse models and negative in rat models. Similarly, the compounds were predicted to be mutagens by Ames test. The predicted toxicity in algae and fish such as daphina, medaka and minnow were displayed varying results however, these results can be considered as features for ideal lead molecules. The in vitro Ames test results in TA100 strain were predicted to be low risk and medium risk respectively. Thus, virtual screening and chemoinformatics features of the two compounds showed that these compounds probably possess ideal drug likeliness, pharmacokinetics and toxicity profile required to be considered the lead for structure based drug discovery.

### Table 4. The ADME features of the selected compounds predicted by PreADMET web server.

| Compound | IUPAC Name                                      | BB (C<sub>brain</sub>/ C<sub>blood</sub>)<sup>a</sup> | Buffer solubility (mg/L) | Caco2 (nm/s)<sup>b</sup> | CYP 2C19 inhibition | CYP 2C9 inhibition | CYP 2D6 inhibition | CYP 3A4 inhibition | HIA<sup>c</sup> (%) | MDCK (nm/s)<sup>d</sup> | PPB (%)<sup>e</sup> | Pure water solubility (mg/L) | Skin permeability (log kp, cm/h)<sup>f</sup> |
|----------|------------------------------------------------|-------------------------------------------------|--------------------------|--------------------------|-------------------|-------------------|-------------------|-------------------|-----------------|------------------|-----------------|-----------------------------|-----------------------------|
| 1        | (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide | 0.343929 | 2093.38 | 20.8564 | Non | 83.106555 | 106.93 | 7.319536 | 479.334 | -3.97404 |
| 2        | (E)-2-(2-aminobenzylidene) hydrazinecarboxamide | 0.343711 | 24.1669 | 0.649922 | Non | 82.159306 | 50.2498 | 5.278023 | 1270.08 | -3.95658 |

### Table 5. The toxicity features of the selected compounds predicted by PreADMET web server.

| Compound | IUPAC Name                                      | Acute algae toxicity | Acute daphina toxicity | Ames test | Carcinogenicity (Mouse) | Carcinogenicity (Rat) | in vitro hERG inhibition | Acute fish toxicity (medaka) | Acute fish toxicity (minnow) | in vitro Ames test result in TA100 strain |
|----------|------------------------------------------------|----------------------|------------------------|-----------|-------------------------|-----------------------|-------------------------|-------------------------------|-------------------------------------|---------------------------------------|
| 1        | (E)-2-(1-(3-nitrophenyl) ethylidene) hydrazinecarboxamide | 0.22763 | 1.43559 | Mutagen | Positive | Negative | Low risk | 2.54523 | 1.70397 | Negative |
| 2        | (E)-2-(2-aminobenzylidene) hydrazinecarboxamide | 0.271746 | 1.21702 | Mutagen | Positive | Negative | Medium risk | 1.83596 | 1.34808 | Negative |

Study of binding potential of compounds with various cancer targets. Each of the three dimensional structures of the selected cancer protein targets (Table 6) were docked with the compounds 1 and 2. The binding potential of these compounds towards the prioritized targets are shown in Table 7. From the dock-
| Gene number | Gene name | Drug target (Gene products) | PDB ID | Type of cancer involved | References |
|-------------|-----------|-----------------------------|--------|-------------------------|------------|
| 1499        | CTNNB1    | β-catenin (Gene products)   | 1JDH   | Gastric cancer, colorectal cancer, endometrial cancer, thyroid cancer, hepatocellular carcinoma | Graham et al.35 |
| 1956        | EGFR      | Epidermal growth factor receptor | 4R3P  | Oral cancer, esophageal cancer, gastric cancer, bladder cancer, choriocarcinoma, cervical cancer, glioma, laryngeal cancer | Park et al.36 |
| 2064        | ERBB2     | Kinase domain of human HER2 (erbB2) | 3PP0  | Gastric cancer, Pancreatic cancer, Bladder cancer, endometrial cancer, ovarian cancer, choriocarcinoma, cervical cancer, breast cancer, cholangiocarcinoma | Aertgeerts et al.37 |
| 595         | CCND1     | Cyclin D1-cyclin-dependent kinase 4 | 2W96   | Hairy cell leukemia, multiple myeloma, oral cancer, esophageal cancer, breast cancer, laryngeal cancer | Day et al.38 |
| P31751      | AKT2      | RAC-beta serine/threonine-protein kinase B | 1GZK  | Lung cancer, neuroblastoma, gastric cancer | Yang et al.39 |

**Table 6.** Selection of probable drug targets from various types of cancers for structure based drug screening. The drug targets were screened based on the virulent function in the metabolic pathways of each type of cancer. The structural coordinates of these drug targets were retrieved from PDB.

| Cancer receptors and PDB ID | Ligand molecules                        | Interacting residues | Cluster RMS (Å) | No. of hydrogen bonds and interacting amino acids | Binding energy (kcal/mol) |
|-----------------------------|----------------------------------------|----------------------|-----------------|-------------------------------------------------|--------------------------|
| β-catenin (PDB ID: 1JDH)    | (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide | Ser106, Pro192, Gln228, Ala230, Lys233 | 0.00            | Nil                                             | −5.9                     |
|                            | (E)-2-(3-aminobenzylidene) hydrazinecarboxamide | Phe21, Lys22, Gln36, Val349, Lys354 | 0.00            | Nil                                             | −5.4                     |
| Epidermal growth factor receptor (EGFR) (PDB ID: 4R3P) | (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide | Arg836, Lys860, Tyr869, Ala871, Gly873 | 0.00            | 02 Arg836,Tyr869                               | −5.8                     |
|                            | (E)-2-(3-aminobenzylidene) hydrazinecarboxamide | His393, Trp880, Lys879, Lys913, Gly917, Asp916 | 0.00            | 01 Asp916                                       | −5.7                     |
| Kinase domain of human HER2 (ERBB2) (PDB ID: 3PP0) | (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide | Leu755, Gly865, Phe731 | 0.00            | Nil                                             | −6.5                     |
|                            | (E)-2-(3-aminobenzylidene) hydrazinecarboxamide | Leu755, Ala758, Ala763, Ghu766 | 0.00            | 01 Asn758                                       | −6.2                     |
| Cyclin D1-cyclin-dependent kinase 4 (PDB ID: 2W96) | (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide | Pro183, Leu186, Gln184, Thr190, Trp238, Phe278, Pro280 | 0.00            | 02 Pro183,Thr190                               | −6.7                     |
|                            | (E)-2-(3-aminobenzylidene) hydrazinecarboxamide | Gln184, Leu186, Gln188, Phe278, Pro280 | 0.00            | Nil                                             | −6.0                     |
| RAC-beta serine/threonine-protein kinase B (PDB ID: 1GZK) | (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide | Thr231, Tyr177, Lys285, Lys420 | 0.00            | 01 Tyr231                                      | −5.7                     |
|                            | (E)-2-(3-aminobenzylidene) hydrazinecarboxamide | Gln236, Phe238, Gln279, Asp440 | 0.00            | 01 Asp440                                      | −5.4                     |

**Table 7.** The binding potential of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and (E)-2-(2-aminobenzylidene) hydrazinecarboxamide towards selected drug targets of various types of cancers predicted by molecular docking studies by AutoDock Vina.

In docking studies, it is clear that each of the synthesized compounds possessed good binding potential towards five selected cancer targets with minimum binding energy (kcal/mol), cluster root mean square deviation, number of hydrogen bond stabilization and maximum number of interacting residues. The molecular docking studies clearly showed that the synthesized compound 1 demonstrated good binding potential to all the five selected cancer targets. The compound showed good binding to β-catenin (PDB ID: 1JDH) with binding energy of −5.9 kcal/mol. The main residues present in the binding cavity were found to be Ser105, Pro192, Gln228, Ala230, and Lys233. The compound demonstrated the potential binding with epidermal growth factor receptor (EGFR) (PDB ID: 4R3P) with binding energy of −5.8 kcal/mol. Arg836, Lys860, Tyr869, Ala871, and Gly873 were identified to be the main residues present in the binding cavity of the receptor. The interaction also stabilized by two hydrogen bonds with the residues such as Arg836 and Tyr869. Similarly, the compound exhibited good binding potential to kinase domain of human HER2 (ERBB2) (PDB ID: 3PP0) with binding energy of −5.7 kcal/mol. The major residues present in the binding cavity were identified to be Leu755, Gly865, and Phe731; however, no hydrogen bond involved in the interaction (Fig. 5c). The compound also showed potential binding to cyclin D1-cyclin-dependent kinase 4 (PDB ID: 2W96) with a binding energy of −6.7 kcal/mol. The main residues present in the binding cavity were found to be Pro183, Leu186, Gln184, Thr190, Trp238, Phe278, and Pro280. The interaction also stabilized by two hydrogen bonds with the residues Pro183 and Thr190. Similarly, compound 1 also demonstrated good binding with RAC-beta serine/threonine-protein kinase B (PDB ID: 1GZK) with binding energy of −5.4 kcal/mol.
Figure 5. The binding potential of the compound 1 to the five selected cancer receptor studied by molecular docking (a) The best binding Interaction of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and β-catenin predicted by molecular docking with binding energy of − 5.9 kcal/mol. The ligand is highlighted in green coloured stick figures. The amino acid residues present in the binding activity of the β-catenin receptor is also highlighted (b) The best binding Interaction of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and Epidermal growth factor receptor (EGFR) with binding energy of − 5.8 kcal/mol. Thick green coloured stuck indicate hydrogen bonding. The ligand is highlighted in green coloured stick figures and the amino acid residues present in the binding activity of the EGFR receptor is also shown in the figure (c) The best binding Interaction of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and Kinase domain of Human HER2 (erbB2) predicted by molecular docking with binding energy of − 6.5 kcal/mol. The ligand is highlighted in green coloured stick figures and the amino acid residues present in the binding activity of the EGFRK receptor are also highlighted. (d) The best binding Interaction of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and Cyclin D1-cyclin-dependent kinase 4 with binding energy of − 6.5 kcal/mol. Thick green coloured stuck indicate hydrogen bonding. The ligand is highlighted in green coloured stick figures and the amino acids present in the binding activity of Cyclin D1-cyclin-dependent kinase 4 is also highlighted. (e) The best binding Interaction of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and RAC-beta serine/threonine-protein kinase B with binding energy of − 6.5 kcal/mol. The ligand is highlighted in green coloured stick figures and the amino acids present in the binding activity of the RAC-beta serine/threonine-protein kinase B receptor is also shown in the figure. The part shown in uppercase indicate the molecular surface display of the best binding pose of the interaction between the compound 1 and selected cancer receptor.
The molecular docking studies also demonstrated that the synthesized compound 2 exhibited potential binding to all of the five selected cancer targets. The compound showed a good binding to β-catenin (PDB ID: 1JDH) with binding energy of −5.9 kcal/mol. The main residues present in the binding cavity were found to be Thr231, Tyr177, Lys285 and Lys420 (Fig. 5c). The molecular docking studies also demonstrated that the synthesized compound 2 exhibited potential binding to all of the five selected cancer targets. The compound showed a good binding to β-catenin (PDB ID: 1JDH) with binding energy of −5.9 kcal/mol. The main residues present in the binding cavity were found to be Thr231, Tyr177, Lys285 and Lys420 (Fig. 5c).

When the binding of two synthesized compounds was predicted against calf thymus (CT) DNA (PDB ID: 2DYW) by molecular docking studies, the modeling studies demonstrated that both the compounds showed profound binding towards the DNA. The compound 1 (1, 2-amino shift in (E)-2-(1-(3-aminophenyl) ethyldiene) hydrazinecarboxamide) showed interaction with DNA at DG10, and the interaction stabilized with a hydrogen bond. The major residues present in the binding pose are Thr231, Gly917, Lys766 and the interaction is also stabilized by a hydrogen bond at Asn758 (Fig. 6b). Similarly, the compound 2 exhibited good binding potential to kinase domain of human HER2 (ERBB2) (PDB ID: 3P00) with binding energy of −6.2 kcal/mol. The major residues present in the binding pose are Leu755, Ala763, Glu766 and the interaction is estimated to be −6.71 kcal/mol. The ligand efficiency and intermolecular energy were found to be −0.48 and −7.24 kcal/mol respectively. The inhibition constant was found to be 12.13 µM. Similarly, when the binding of the compound 2 ((E)-2-(2-aminobenzylidene) hydrazinecarboxamide) towards the CT-DNA (PDB ID: 2DYW) were predicted by molecular docking studies, the modeling studies revealed that both the compounds showed significant binding with the DNA. The compound 2 showed profound binding with DNA with the binding energy of −6.71 kcal/mol. The compound interacted within the two strands of the DNA and the interaction stabilized with DG6 and DG7 with two hydrogen bonds (Fig. 7b). The ligand efficiency and intermolecular energy were found to be −0.47 and −6.99 kcal/mol respectively. The inhibition constant was found to be 34.13 µM. From the interaction modeling by molecular docking, it is clear that both compound 1 and compound 2 interacted within both the strands of the DNA in almost the nearer binding sites. As shown in the experimental studies, the computational interaction modeling of the molecules and the DNA showed profound binding and the theoretical prediction is comparable with the experimental finding. The theoretical binding constants, inhibition constants, and binding energies are comparable with the experimental finding that showed a concurrent result. As shown in the experimental studies, computational modeling also suggested that the DNA binding potential of the compounds depends on the position of the amine group in the aromatic ring of the molecules.

The synthesized compounds 1 and 2 demonstrated good drug likeness, pharmacokinetic features, ideal toxicity parameters and good binding with all the five selected cancer drug targets. β-catenin is involved in various types of cancers such as gastric cancer, colorectal cancer, thyroid cancer, hepatocellular carcinoma and studies suggested that it is one of the potential targets for drug development.

The binding energy of the interaction is stabilized by various amino acids. Epidermal growth factor receptor (EGFR) is one of the major cancer receptor, responsible for several types of cancer such as oral cancer, esophageal cancer, gastric cancer, bladder cancer, choriocarcinoma, cervical cancer, glioma and laryngeal cancer. The target can be prioritized as one of the potential cancer target. Both the synthesized compounds were found to be equally potential as the binding energy is almost same. Kinase domain of human HER2 (ERBB2) is another important target that has potential role in several types of cancer such as gastric cancer, pancreatic cancer, bladder cancer, endometrial cancer, ovarian cancer, choriocarcinoma, cervical cancer, breast cancer and cholangiocarcinoma and can be considered as one of the potential target for anti-cancerous compound development. Cyclin D1-cyclin-dependent kinase 4 is one of the major types of the cancer receptor which involved in various types of cancer such as hairy cell leukemia, multiple myeloma, oral cancer, esophageal cancer, breast cancer and laryngeal cancer. Both the compound found to be interacted with this cancer receptor and probably possess good inhibitory potential to the cancer target. The present study suggested that compound 1 possesses better binding potential to most of the selected cancer receptor, thus the compound probably considered as potential inhibitors towards all the five cancer receptors. Compound 2 also showed comparable binding potential with stable interactions with minimum binding energy.

There are several studies suggested the anticancer properties of various synthesized derivatives of hydrazinecarboxamide. To the best of our knowledge, this is the first study demonstrated the binding potential of the synthesized compounds 1 and 2 towards five selected targets which are considered as the major targets in various types of cancer. The anticancerous properties of the synthesized compounds were suggested based on computational virtual screening and molecular docking studies. Thus, molecular dynamic simulations studies can be performed to confirm the stability of the docked complexes of the synthesized compounds and prioritized cancer targets. Further, the efficiency and inhibitory potential of the synthesized compounds towards the prioritized targets needed to be tested at lower micro molar concentration by appropriate in vitro assays to validate...
Figure 6. The binding potential of the compound 2 to the five selected cancer receptor studied by molecular docking (a) The best binding interaction of (E)-2-(2-aminobenzylidene) hydrazinecarboxamide and β-catenin predicted by molecular docking with binding energy of − 5.9 kcal/mol. The ligand is highlighted in green coloured stick figures. The amino acid residues present in the binding activity of the β-catenin receptor is also highlighted (b) The best binding interaction of (E)-2-(2-aminobenzylidene) hydrazinecarboxamide and Epidermal growth factor receptor (EGFR) with binding energy of − 5.7 kcal/mol. Thick green coloured stick indicate hydrogen bonding. The ligand is highlighted in green coloured stick figures and the amino acid residues present in the binding activity of the EGFR receptor is also shown in the figure (c) The best binding interaction of (E)-2-(2-aminobenzylidene) hydrazinecarboxamide and Kinase domain of Human HER2 (erbB2) predicted by molecular docking with binding energy of − 6.2 kcal/mol. The ligand is highlighted in green coloured stick figures and the amino acid residues present in the binding activity of the EGFRK receptor are also highlighted. (d) The best binding interaction of (E)-2-(2-aminobenzylidene) hydrazinecarboxamide and Cyclin D1-cyclin-dependent kinase 4 with binding energy of − 6.0 kcal/mol. Thick green coloured stick indicate hydrogen bonding. The ligand is highlighted in green coloured stick figures and the amino acids present in the binding activity of Cyclin D1-cyclin-dependent kinase 4 is also highlighted. (e) The best binding interaction of (E)-2-(2-aminobenzylidene) hydrazinecarboxamide and RAC-beta serine/threonine-protein kinase B with binding energy of − 5.4 kcal/mol. The ligand is highlighted in green coloured stick figures and the amino acids present in the binding activity of the RAC-beta serine/threonine-protein kinase B receptor is also shown in the figure. The part shown in uppercase indicate the molecular surface display of the best binding pose of the interaction between the compound 2 and selected cancer receptor.
the prediction. The finding in the current study surely provides significant insights for further experimentations and future investigations.

**Hirshfeld surfaces analysis.** Hirshfeld surface analysis gives information on a crystal contained unique information on each molecule by dividing the crystal space into non-overlapping molecular volume. Which allows us to excess intermolecular interactions. Here, dnorm is the parameter for normalized contact distance, which is based on (di), (de) and (r vDW) van der Waals radii of atom, which gives the equation as follows:

\[
d_{\text{norm}} = \left( \frac{d_i - r_{vdw}^i}{r_{vdw}^i} \right) + \left( \frac{d_e - r_{vdw}^e}{r_{vdw}^e} \right)
\]

The Hirshfeld analysis resolves and quantifies the intercontact between atoms in the crystal structure. Fig. 8. The red spots over the Hirshfeld surface images shows the involved intercontact in the intermolecular interaction.
interactions\textsuperscript{50}. The strong hydrogen bond spots as dark red region which is the result of short intercontact between the atoms showed on the dnorm surface and light red spots indicated the other intermolecular contact between the atoms. The electrostatic potential range is between plotted in $-0.030$ a.u. to $+0.030$ a.u on Hirshfeld surfaces based on Hartree–Fock theory and which is showed electrostatic potential over the Hirshfeld surfaces in Fig. 9 red region (hydrogen acceptor) negative. And blue region (hydrogen donor) positive electrostatic potentials\textsuperscript{51}. The intercontacts with respect to di and de plotted for 2D fingerprint plots and quantified by using visualization of the Hirshfeld surfaces (Fig. 10). The intercontacts were found to be C…H (13.3%), H…H (47.6%), N…H (4.1%), O…H (9.1%). The intercontacts generated from the 2D Finger print plots are shown in Fig. 10. The major contributions of intercontacts Hirshfeld analysis are from H…H, C…H, O…H and S…H when compared to other intercontacts.

Conclusion
The C-demethylation and 1,2 amino shift in phenyl ring takes place simultaneously in compound 1 under mild conditions and became molecule 2. These kind of chemical changes was not reported in a compound to date. Furthermore, compound 2 cannot be made directly from 2-amino benzaldehyde, which has less stability; it is due to presence of aldehyde and amino group in the same molecule. Hence, in future this kind of easy chemical conversion can be used to make novel molecules and might be used in various fields. Nucleic acid interactions of compounds with CT-DNA was carried out, results revealed that they have displayed hyperchromism with bathochromic shift. Generally, this kind of results obtained from metal complexes has positively charged metal ions with nucleic acid gave electrostatic interaction. But these organic molecules 1 and 2 displayed excellent interaction with DNA and the molecular basis of the interaction was predicted by molecular docking studies. The computational virtual screening suggested that synthesized compounds possessed ideal drug likeliness, pharmacokinetic features and toxicity properties and demonstrated profound binding with selected cancer receptors are β-catenin, epidermal growth factor receptor, kinase domain of human HER2, cyclin D1-cyclin-dependent kinase 4 and RAC-beta serine/threonine-protein kinase B. Thus, biological studies of compounds provide ample foundation in the scale up of the applied approaches and nucleic acid interactions and computational prediction probably provides profound scope and application for the screening and designing of novel anticancer lead molecules. The Hirshfeld surface analysis of compound 2 was carried out and fingerprint plots were studied, results revealed that nature of molecular interactions and their contributions to the molecular surface.

Experimental section
Material and methods. All the reagents have been commercially obtained and have been used without further purification. Semicarbazide hydrochloride (99%) and 3-aminoacetophenone (97%) were purchased from Sigma-Aldrich, St. Louis, Missouri, United States. Sodium acetate trihydrate (99.5%), N, N-Dimethylformamide (99.9%), Dimethyl sulfoxide (99.8%) and methanol (99.5%) were obtained from Merck, Kenilworth, New Jersey, United States.
Melting point of the compounds was recorded using capillary tube in Sigma melting point apparatus, Sigma instruments. $^1$H-NMR spectrum obtained in DMSO-d$_6$ using tetramethylsilane (TMS) on Advanced 200.13 MHz NMR spectrometer. $^{13}$C-NMR spectrum was obtained in DMSO-d$_6$/CDCl$_3$ using Bruker-300 MHz NMR. Single X-ray diffraction data was recorded on a Bruker Kappa Apex2 CCD diffractometer. The LC–MS of the compound 1 was recorded on Thermo, LCQ Deca XP MAX. GC–MS of molecule 2 was collected by Xevo G2-XS QT.

**Figure 10.** Fingerprint plots: Hirshfeld surfaces and 2D fingerprint plots of compounds and outline of the full fingerprint is shown in gray and other intercontacts from 2 to 10. di is the closest internal distance from a given point on the Hirshfeld surface and de is the closest external contacts.
Synthesis of (E)-2-(1-(3-aminophenyl)ethylidene)hydrazinecarboxamide (1). The mixture of semicarbazide hydrochloride [1.11 g, 0.01 m] and sodium acetate trihydrate [1.63 g, 0.012 m] in water stirred for 15 min, added methanol containing 3-aminacetophenone [1.35 g, 0.01 m] continued 10 min stirring. The colourless precipitate was filtered, washed with cold methanol and air dried. (Scheme 2). Yield: 78.0%, M.P: 166 °C. 1H-NMR (200.12 MHz, DMSO-d6, ppm) δ: 2.19 (s, 3H, CH3), 2.59 (s, 2H, NH2), 3.08 (s, DMSO), 4.20 (s, 2H, CONH2), 6.67–7.14 (m, 4H, Ar), 8.72 (s, 1H, NH). 13C NMR (300MHZ, DMSO-d6 and CDCl3, ppm) δ: 156.64 (1C, C-NH2), 146.42 (1C, C=O), 144.26 (1C, C=N) 137.91–110.72 (5C, Ar), 12.31 (1C, CH3), 77.43–76.56 (CDCl3), 39.57–37.87 (DMSO).LC–MS (m/z): 193.09 [M + 1].

Conversion of (E)-2-(1-(3-aminophenyl)ethylidene)hydrazinecarboxamide (1) to (E)-2-(2-aminobenzylidene)hydrazinecarboxamide (2). (E)-2-(1-(3-aminophenyl)ethylidene)hydrazinecarboxamide (Scheme 2) is dissolved in DMF/DMSO, kept at room temperature about 90 days. The formed dark brown crystals are separated out, washed with water and air dried. M.P: 231 °C. 1H-NMR (200.12 MHz, DMSO-d6, ppm) δ: 3.61 (s, DMSO), 6.37 (s, 2H, CONH2), 6.79–7.69 (m, 4H, Ar), 8.12 (s, 1H, CH = N), 10.18 (s, 1H, NH). 13C NMR (300MHZ, DMSO-d6 and CDCl3, ppm) δ: 154.82 (1C, C-NH2), 154.09 (1C, C = O), 136.75 (1C, C = N), 128.47– 114.23 (5C, Ar), 77.43–76.55  (CDCl3), 38.43–36.76 (DMSO).GC–MS (m/z): 202 [M + 1Na].

X-ray crystallography. The compound 1 was dissolved in polar solvent DMSO and kept for crystallization at room temperature for three months. The colourless solution of compound 1 was slowly changed to dark brown and gave dark brown colour crystals, it is compound 2. A specimen of crystal size 0.2 × 0.17 × 0.15 mm3 was selected for data collection on Bruker Kappa Apex2 CCD diffractometer at 296(2) K. Single crystal X-ray diffractometer equipped with graphite monochromated MoKα (λ = 0.71073) radiation, operated at 40KV and 30 mA. The structure of molecule 2 was solved by direct methods with the olex2.solve and refined with the ShelXL53,54. The crystallographic data of compound 2 are summarized in Table 8.

DNA binding. DNA binding ability of organic molecules 1 and 2 in DMSO are examined in 50 mM Tris–HCl/NaCl buffer solution at pH 7.0. Molar absorbance coefficient of CT-DNA (6600 dm3 mol−1 cm−1) at 260 nm was used to calculate the concentration of nucleic acid55. The CT-DNA in buffer solution gave a ratio of absorbance at 260 and 280 nm (A260/A280) is 1.83, divulged that protein free nature of DNA55. Electronic absorption spectroscopic titrations were performed varying the concentration of nucleic acid from 0 to 2.5 × 10−5 M, while molecules remained constant (0.01 M). After equilibrium was reached (ca.5 min), the spectra were recorded against blank solution containing the same concentration of CT-DNA. The intrinsic binding constant (Kb) of molecules was calculated using following equation56.

\[
\frac{[\text{DNA}]}{(\varepsilon_a - \varepsilon_f)} = \frac{[\text{DNA}]}{(\varepsilon_b - \varepsilon_f)} + \frac{1}{K_b(\varepsilon_b - \varepsilon_f)}
\]

where [DNA] is the concentration of CT-DNA, εa, εb and εf correspond to apparent, bound and free extinction coefficients of compounds 1 and 2. A plot of [DNA]/(εa − εf) Vs [DNA] gave a slope of 1/(εb − εf) and a Y-intercept equal to 1/Kb (εb − εf), Kb is the ratio of the slope to the Y-intercept.

Bioinformatics. Selection of probable drug targets of various types of cancer. Based on the extensive literature survey, the major targets involved in various types of cancer were identified. The description of the cancer drug targets selected in the present study is shown in Table 6. The selected cancer receptors are β-catenin (PDB: 1JDH), Epidermal growth factor receptor (PDB: 4R3P), Kinase domain of human HER2 (PDB: 3PP0), Cyclin D1-cyclin-dependent kinase 4 (PDB: 2W96) and RAC-beta serine/threonine-protein kinase B (PDB: 1GZK).

Preparation of proteins. Three dimensional structure of the selected receptors such as β-catenin (PDB: 1JDH)35, Epidermal growth factor receptor (PDB: 4R3P)36, Kinase domain of human HER2 (PDB: 3PP0)37, Cyclin D1-cyclin-dependent kinase 4 (PDB: 2W96)38 and RAC-beta serine/threonine-protein kinase B (PDB: 1GZK)39 were retrieved from Protein Data Bank. The coordinate files were analyzed and edited by adding polar hydrogen
atoms with the help of AutoDock Tools\textsuperscript{57}. The binding cavities present in the selected receptors were predicted by Q-SiteFinder\textsuperscript{58} and DEPTH server\textsuperscript{59}. The structures were saved in pdbqt format.

**Preparation of structure of ligands.** The 2D structure of these ligands (Scheme 1) was converted into 3D structures and structure optimization was carried out by ACD 3D viewer\textsuperscript{60}. The 3D structure of these ligands was saved in pdb format. The ligand structure was loaded into MGL Tools and the root atoms, number of torsion, rotatable and nonrotatable bonds were assigned and the file was saved in pdbqt format for docking studies.

**Computer aided virtual screening of the ligand molecules.** The drug likeliness features of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and (E)-2-(2-aminobenzylidene) hydrazinecarboxamide were analyzed by the computational tools such as PreADMET\textsuperscript{61} and SwissADME\textsuperscript{62}. The main filters used for the drug likeliness are Lipinski’s rule of five, CMC-like rule, MDDR-like rule and WDI-like rule available in PreADMET\textsuperscript{63–66} and Ghose filter, Veber filter, Egan filter and Muegge filter were available in SwissADME. The molar refractivity, Log P, Topological polar surface area (TPSA) and bioavailability score were also predicted by SwissADME. Further, the adsorption, distribution, metabolism and excretion (ADME) features of these lead molecules by various statistical models available in PreADMET such as blood brain barrier (BBB) penetration, buffer solubility, human intestinal absorption (HIA), heterogeneous human epithelial colorectal adenocarcinoma (caco2) cell permeability, Madin Darby canine kidney (MDCK) cell permeability, plasma protein binding, CYP2C19 inhibition, CYP 2C9 inhibition, CYP2D6 inhibition, CYP3A4 inhibition, CYP3A4 substrate, Pgp inhibition, pure water solubility and skin permeability assays. The toxicity of the ligands was predicted by various options available in PreADMET such as acute algae toxicity, carcinogenicity in mouse rat models, in vitro hERG inhibition, acute fish toxicities in daphnia, medaka and minnow models and in vitro Ames test.

**Molecular docking studies.** Interaction modelling of the synthesized compounds and probable cancer targets. The binding potential of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and (E)-2-(2-aminobenzylidene) hydrazinecarboxamide to the selected cancer receptors were studied by molecular docking by AutoDock Vina\textsuperscript{67}. The grid box was assigned for each cancer target by setting the 3D coordinates for the binding pocket predicted by various binding pocket prediction server mentioned previously. The x, y, z coordinates for binding pockets in each target were assigned in the configuration file. The total grid data per map for each of

| Identification code | NSC       |
|---------------------|-----------|
| CCDC No             | 1864018   |
| Empirical formula   | C\textsubscript{8}H\textsubscript{10}N\textsubscript{4}O   |
| Formula weight      | 178.20    |
| Temperature         | 296 K     |
| Crystal system      | monoclinic |
| Space group         | C2/c      |
| a                   | 13.2228(10) Å |
| b                   | 5.2826(4) Å   |
| c                   | 24.889(3) Å   |
| α                   | 90°       |
| β                   | 104.092(8)°  |
| γ                   | 90°       |
| Volume              | 1486.2(3) Å\textsuperscript{3} |
| Z                   | 8         |
| P\textsubscript{val} | 1.404 cm\textsuperscript{3} |
| μ                   | 0.099 mm\textsuperscript{-1} |
| F(000)              | 752.0     |
| Crystal size        | 0.2 × 0.17 × 0.15 mm\textsuperscript{3} |
| Radiation           | MoKa (λ = 0.71073) |
| 2θ range for data collection | 6.752 to 49.984° |
| Index ranges        | −15 ≤ h ≤ 15, −5 ≤ k ≤ 6, −29 ≤ l ≤ 29 |
| Reflections collected | 5254        |
| Independent reflections | 1491 [R\textsubscript{int} = 0.0387, R\textsubscript{gmax} = 0.0279] |
| Data/restraints/parameters | 1491/0/119 |
| Goodness-of-fit on F\textsuperscript{2} | 1.089 |
| Final R indexes [I > 2σ (I)] | R\textsubscript{I} = 0.0698, wR\textsubscript{I} = 0.2087 |
| Final R indexes [all data] | R\textsubscript{I} = 0.0776, wR\textsubscript{I} = 0.2189 |
| Largest diff. peak/hole | 0.36/−0.47 e Å\textsuperscript{3} |

**Table 8.** Crystal data and structure refinement of compound 2.
the selected receptor was assigned by fixing the values for number of points in x, y, z-dimensions (size_x, size_y, size_z). Further, the parameter values for center grid box of each receptor (center_x, center_y, center_z) were assigned as per the standard protocol. The values for exhaustiveness in the docking simulation were assigned as per standard (Trott and Olson 2010). The molecular docking simulation was performed through command prompt. The output (log) files of the best nine confirmations were generated and conformations were ranked according to minimum binding energy (kcal/mol), docking score, cluster RMSD, number of hydrogen bond formed and the interacting residues present at the close proximity of 1.0 Å VVD scaling factor. Out of which, the first confirmations were selected as the best predicted model. The receptor ligand complex was visualized in MGL tools and PyMol.

Interaction modeling of the synthesized compounds and CT-DNA. The binding potential of (E)-2-(1-(3-aminophenyl) ethylidene) hydrazinecarboxamide and (E)-2-(2-aminobenzylidene) hydrazinecarboxamide towards the CT-DNA was predicted by molecular docking studies. The 3D structure of the DNA (PDB ID: 2DYW) was retrieved from the PDB database. The structure was analysed thoroughly and the bound form of the ligand was removed and the targets were prepared for docking studies as per the standard protocol and to generating electrostatic potential with TONTO. The program explores molecular packing and provides surface information on different types of intermolecular interactions of the crystal and can be identified and their contribution of individual contact by 2D fingerprint plots (FP) shown in the colour plot.

Received: 5 August 2020; Accepted: 1 December 2020
Published online: 14 December 2020

References
1. Haronhally, N. V., Cherita, C., Bhatt, P. & Anu Appaiah, K. A. Antiaflatoxinogenic and antimicrobial activities of Schiff bases of 2-hydroxy-4-methoxybenzaldehyde, cinnamaldehyde, and similar aldehydes. J. Agric. Food Chem. 65, 8773–8778 (2017).
2. Raj, P., Singh, A., Singh, A. & Singh, N. Syntheses and photoophysical properties of Schiff Base Ni(II) complexes: application for sustainable antibacterial activity and cytotoxicity. ACS Sustain. Chem. Eng. 5, 6070–6080 (2017).
3. Wei, H., Fan, Y. & Gao, Y. Q. Effects of urea, tetramethyl urea, and trimethylamine N-oxide on aqueous solution structure and solvation of protein backbones: a molecular dynamics simulation study. J. Phys. Chem. B 114, 557–568 (2010).
4. Thurston, J. H., Hunter, N. M., Wayment, L. J. & Cornell, K. A. Urea-derived graphitic carbon nitride (u-g-C3N4) films with highly enhanced antimicrobial and sporicidal activity. J. Colloid Interface Sci. 505, 910–918 (2017).
5. Islam, K., Ali, S. M., Jesmin, M. & Khanam, J. A. In vivo anticancer activities of benzophenone semicarbazone against Ehrlich ascites carcinoma cells in swiss albino mice. Asian Pac. J. Trop. Biomed. Carcin. 99–110 (2017).
6. Li, K. K., Luo, C., Wang, D., Jiang, H. & Zheng, G. Chemical and biochemical approaches in the study of histone methylation and demethylation. Med. Res. Rev. 295–308 (2016).
7. JadHAV, A. A., Dhanwe, V. P. & Khanna, P. K. Synthesis of novel Zn(II) and Cd(II) complexes of semicarbazones and their utility as precursors for respective metal selenide quantum dots. Polyhedron 123, 99–110 (2017).
8. Layana, S. R. et al. Synthesis, spectral characterization and structural studies of a novel O, N donor semicarbazone and its binuclear copper complex with hydrogen bonded stabilized lattice. J. Mol. Struct. 1157, 579–586 (2018).
9. Li, K. K., Luo, C., Wang, D., Jiang, H. & Zheng, G. Chemical and biochemical approaches in the study of histone methylation and demethylation. Med. Res. Rev. 32, 815–867 (2012).
10. Kohli, R. M. & Zhang, Y. TET enzymes. TDG and the dynamics of DNA demethylation. Nature 502, 472–479 (2013).
11. Scourzic, L., Mouri, E. & Bernard, O. A. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 7, 1–16 (2015).
12. Nishioka, K., Daidoji, T. & Nakaya, T. Demethylation around the transcriptional start site of the IFN-β gene induces IFN-β production and protection against influenza virus infection. Biochem. Biophys. Res. Commun. 520, 269–276 (2019).
13. Pacis, A. et al. Gene activation precedes DNA demethylation in response to infection in human dendritic cells. PNAS 116, 6938–6943 (2019).
14. Bayraktar, G. & Kreutz, M. R. The role of activity-dependent DNA demethylation in the adult brain and in neurological disorders. Front. Mol. Neurosci. 11, 1–7 (2018).
15. Coop, A. & Rice, K. C. Methods of O-Demethylation and n Deprotection (Springer, New York, 2002).
16. Wang, Z., Wang, X. & Nishiura, Y. PPh3-assisted esterification of acyl fluorides with ethers via C(sp3)–O Bond Cleavage Accelerated by TBAT. Catalysis. 9, 1–12 (2019).
17. Paul, K. A. et al. The decarbethoxylation of geminal dicarbethoxy compounds. Tetrahedron Lett. 8, 215–217 (1967).
18. Kedderis, G. L., Koop, D. R. & Hollenberg, P. F. N-demethylation reactions catalyzed by chloroperoxidase. J. Biol. Chem. 255, 10174–10182 (1980).
19. Cressman, H. W. J-N-methyl-1-naphthylcarbamide. Org. Synth. 3, 608 (1955).
22. David, C., Neal, W. & Stephen, A. Process for the preparation of Paroxetine. PCT (2001).
23. Jones, K., Roset, X., Rossiter, S. & Whittfeld, P. Demethylation of 2,4-dimethoxyquinolines: the synthesis of atanine. Org. Biomol. Chem. 1, 4380–4383 (2003).
24. Lawson, J. A. & DeGraw, J. I. An improved method for O-demethylation of codeine. J. Med. Chem. 20, 165–166 (1977).
25. Wetmore, S. D., Smith, D. M. & Radom, L. Enzyme catalysis of 1,2-amino shifts: the cooperative action of B6, B12, and aminomutases. J. Am. Chem. Soc. 123, 8678–8689 (2001).
26. Center for Drug Evaluation and Research. Advancing health through innovation. New Drug Therapy Approvals (2018).
27. Krause, M., Foka, H. & Gobis, K. Pharmacological potential and synthetic approaches of imidazo [4,5-b] pyridine and imidazo [4,5-c] pyridine derivatives. Molecules 22, 1–25 (2017).
28. Torres, M. et al. Raman and infrared studies of platinum-based drugs: cisplatin, carboplatin, oxaliplatin, nedaplatin, and heptaplatin. J. Phys. Chem. A 122, 6934–6952 (2018).
29. Sennappan, M., Murali Krishna, P., Ranganathan, R. & Sivakami Sundari, P. Synthesis, characterization, nucleic acid interaction and photoluminescence properties of (E)-(2-(2-hydroxybenzylidene)hydrazinyl)(pyridin-4-yl)thiophen-2-yl)methaniminium Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes. J. Mol. Struct. 1179, 86–91 (2019).
30. Elemike, E. E., Onwudiwe, D. C., Nwankwo, H. U. & Hosten, E. C. Synthesis, crystal structure, electrochemical and anti-corrosion studies of Schiff base derived from o-tolidine and o-chlorobenzaldehyde. J. Mol. Struct. 1136, 253–262 (2017).
31. Sennappan, M., Murali Krishna, P. & Hari Krishna, R. Facile synthesis, characterisation, nucleic acid interaction and photoluminescence properties of (E)-furan-2-yl(2-(2-hydroxybenzylidene)hydrazinyl) methaniminium and its Mn(II), Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) complexes. J. Mol. Struct. 1178, 333–340 (2019).
32. Gatto, C. C., Lima, I. J. & Chagas, M. A. S. Supramolecular architectures and crystal structures of gold (III) compounds with semicarbazones. Supramol. Chem. 29, 296–307 (2017).
33. Lewis, M., Barnes, C. L. & Glaser, R. The supramolecular architecture of 4-aminoacetophenone (1-(4-fluorophenyl)ethylidene) hydrazide hydrate. Double T-contacts and extremely low-density water layers in a mixed azine. Can. J. Chem. 76, 1371–1378 (1998).
34. Ismail, H. et al. Synthesis, characterization, and pharmacological evaluation of selected aromatic amines. J. Chem. 465286, 1–9 (2015).
35. Graham, T. A., Ferkey, D. M., Mao, F., Kimelman, D. & Xu, W. Tcf4 can specifically recognize beta-catenin using alternative conformations. Nat. Struct. Biol. 8, 1048–1052 (2001).
36. Cui, C., Zhou, X., Zhang, W., Qu, Y. & Ke, X. Is β-Catenin a druggable target for cancer therapy?. Trends Biochem Sci. 43, 623–634 (2018).
37. Chandra, S. & Kumar, S. Synthesis, spectroscopic, anticancer, antibacterial and antifungal studies of Schiff base derived from o-toluidine and o-chlorobenzaldehyde. J. Mol. Struct. 1065, 378–392 (2002).
38. Sennappan, M., Murali Krishna, P. & Hari Krishna, R. Facile synthesis, characterization, nucleic acid interaction and photoluminescence properties of (E)-(2-(2-hydroxybenzylidene)hydrazinyl)(pyridin-4-yl)thiophen-2-yl)methaniminium Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes. J. Mol. Struct. 1179, 86–91 (2019).
39. Yang, J. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 286, 18756–18765 (2011).
40. Day, P. J. et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl. Acad. Sci. USA 106, 4166–4170 (2009).
41. Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: over expression and therapeutic implications. Mol. Biol. Int. 852748, 1–9 (2014).
42. Johnson, N. & Shapiro, G. Cyclin-dependent kinase 4/6 inhibition in cancer therapy. Cell Cycle 11, 3913–3918 (2012).
43. Morrow, J. K. et al. Recent development of anticancer therapeutics targeting Akt. Recent Pat Anticancer Drug Discov. 6, 146–159 (2011).
44. Kamal, A. et al. Synthesis and anticancer activities of new Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4] triazol-1-[3-b]-[1,2,4]thiadiazine 5,5-diones. Med. Chem. 7, 165–172 (2011).
45. Sheldrick, G. M. SHELT - Integrated space-group and crystal-structure determination. Acta Crystallogr. C 71, 3–8 (2015).
46. Sennappan, M., Murali Krishna, P., Hosamani, A. A. & Hari Krishna, R. Synthesis, characterization, nucleic acid interactions and photoluminescent properties of methaniminium hydrazone Schiff base and its Mn(II), Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) complexes. J. Mol. Struct. 1187, 333–340 (2019).
47. Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009).
48. Laurie, A. T. & Jackson, R. M. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21, 1905–1916 (2005).
49. Tan, K. P., Nguyen, T. B., Patel, S., Varadarajan, R. & Madhusudhan, M. S. Depth: Web server to compute depth, cavity sizes, and potential small-molecule ligand-binding cavities and predict the pKa of ionizable residues in proteins. Nucleic Acids Res. 41, W314–W321 (2013).
50. Veber, D. F. Discovery of latent molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615–2625 (2002).
51. Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 1–13 (2017).
63. Ghose, A. K., Viswanadhan, V. N. & Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. I. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1, 55–68 (1999).
64. Teague, S. J., Davis, A. M., Leeson, P. D. & Oprea, T. I. The design of lead like combinatorial libraries. Angew Chem Int Ed Engl. 38, 3743–3748 (1999).
65. Oprea, T. I. Property distribution of drug related chemical databases. J. Comput. Aided Mol. Des. 14, 251–264 (2000).
66. Lipinski, C. A. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv. Drug Deliv. Rev. 101, 34–41 (2016).
67. Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 31, 455–461 (2010).
68. Seeliger, D. & De Groot, B. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol Des. 24, 417–422 (2010).
69. Macrae, C. F. et al. Mercury CSD 2.0—new features for the visualization and investigation of crystal structures. J. Appl. Cryst. 41, 466–470 (2008).
70. Wolff, S. K. et al. CrystalExplorer (Version 3.0) (University of Western Australia, Perth, 2012).
71. Seth, S. K. Tuning the formation of MOFs by pH influence: X-ray structural variations and Hirshfeld surface analyses of 2-amino-5-nitropyridine with cadmium chloride. Cryst. Eng.Commun. 15, 1772–1781 (2013).
72. Seth, S. K. Structural elucidation and contribution of intermolecular interactions in O-hydroxy acyl aromatics: Insights from X-ray and Hirshfeld surface analysis. J. Mol. Struct. 1064, 70–75 (2014).

Author contributions
M.S. performed the synthesis of compounds and DNA binding studies, interpreted data and prepare the final manuscript. S.S. executed computer aided virtual screening and its writing. P.B.M. completed refinement of single X-RD data and Hirshfeld surfaces computational analysis and S.S.G. gave single X-RD data.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-020-79027-1.

Correspondence and requests for materials should be addressed to M.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020